Vancouver, British Columbia - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) ('Entheon' or the 'Company'), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide a corporate update on its operations and progress on its strategic initiatives, including an update on its financial position and near-term revenue generation opportunities resulting from the launch of HaluGen's Psychedelic Genetic Test kit.

HaluGen Test Kit Launch:

HaluGen Life Sciences, Entheon's wholly-owned subsidiary, launched its psychedelics pre-screening platform and DNA test kit in Canada on April 6, 2021 and expects the kits to be available for sale in the US market by the end of May. The first of its kind psychedelics test kit provides genetic, personal and familial insights to better inform one's psychedelic assisted therapy experience.

Entheon is pleased to report that the ordering platform for the test kits is fully functional and sales have commenced. The Company is also exploring direct-to-consumer marketing partnerships with several commercial partners to accelerate awareness and growth of sales in multiple jurisdictions.

'Not only does this kit represent a huge step forward for personalized medicine as it relates to psychedelic therapy, it is also Entheon's first revenue stream. We anticipate strong market demand for this product; we're currently working to develop commercial partnerships for the mass uptake of this test that will drive sales and revenue,' said Timothy Ko, Chief Executive Officer of Entheon. 'The commencement of commercial sales of the DNA test kits continue to advance our mission: to play a market leading role in developing psychedelic assisted therapies and tools to treat substance use disorders, simultaneously creating and growing shareholder value.'

Entheon strongly believes the DNA test kits will assist patients and physicians make better informed choices around psychedelic treatment, resulting in improved patient outcomes.

The HaluGen test kit is a relevant example as it is applicable to all psychedelic drugs and further signals Entheon's interest in working beyond DMT and more broadly within the entirety of the psychedelic sector as it continues to evolve. As such, the Company is committed to the development of tools, products and services that span Ketamine, psychedelics and other drugs.

Strategy Partnerships in EEG and Ketamine Therapy:

Entheon's partnership with Divergence Neuro Tech continues to progress well. The team at Divergence has received and is processing key EEG data from Entheon's academic partners and is developing AI and Machine Learning based models and biomarkers to better understand the neurophysiological characteristics of the DMT experience. Entheon is also seeking to expand the scope of Divergence's investigation to include other drugs, ultimately to inform Entheon's EEG biomarker platform to assist physicians overseeing the care of individuals receiving psychedelic therapy.

As per its release, dated January 4, 2021, Entheon announced a US$200,000 investment in Heading Health for a 5% stake for direct exposure to the ketamine-assisted therapy space, including Spravato, an FDA approved Ketamine product that is eligible for insurance reimbursement. Entheon believes in investing in industry leaders and is excited about further research collaborations with Heading Health to advance its product development.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products ('DMT Products') for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

On Behalf of the Company,

'Timothy Ko'

Timothy Ko, CEO

Contact:

Entheon Biomedical Corp.

Joseph Cullen

Investor Relations

Telephone: +1 (778) 919-8615

Joe@entheonbiomedical.com

https://entheonbiomedical.com/

Media

Bullseye Corporate

Crystal Quast

Telephone: +1 (647) 529-6364

Quast@BullseyeCorporate.com

Cautionary Note on Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to HaluGen's genetic testing kit, potential market, generation of revenue by the Company, the efficacy of the products, the timing and results of any research and phase I clinical trials and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as 'pro forma', 'plans', 'expects', 'will', 'may', 'should', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'potential' or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and timing of future activities of the Company, completion of the milestones in connection with the issuance of the Compensation Shares, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company's operations and the Company's limited operating history.

(C) 2021 Electronic News Publishing, source ENP Newswire